Morphic Holding Inc. Common Stock
Exchange: NASDAQ
Symbol: MORF
SEC CIK: 0001679363
Phone: 9787296480
35 GATEHOUSE DRIVE A2
WALTHAM MA 02451
CEO:
|
Price when page updated: 23.68 Date: 2023-12-01
Company Website:
morphictx.com
|
_Description: Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages Morphic's unique understanding of integrin structure and biology.
IPO YEAR:
2019
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
1177913435.00
|
Beta:
2.79276611687029
|
52 Week High:
93
|
52 Week Low:
29.21
|
52 Week Change:
0.5413184772516246
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
36961618
|
Dividend Rate:
0
|
Dividend Yield:
N/A
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
3 Nov 2022
|
Float:
0
|
return on Equity:
-9.20%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
$170.484M
|
ttmEPS:
0
|
Revenue:
$2.277B
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
-
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
0.40%
|
Return on Assets:
-1.70%
|
Return on Capital:
|
Profit Margin:
-1.60%
|
Price to Sales:
0.61
|
Price To Book:
3.45
|
Short Ratio:
8.73
|
PE Ratio:
0
|
Employees:
89
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Morphic Holding Inc. Common Stock [ MORF ].
__Note: Some Links might not have information for the company.
|
|
